Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next
Author: marsuculix One star, 50 posts Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 639  
Subject: Cabo in Japanese patiente - phase 1 Date: 9/30/2012 5:27 AM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 3
Dear fellow Fools,
if you did not read the report of a phase 1 clinical study presented in Vienna @ ESMO2012 already posted in the Fools universe, you can find the results here:
http://www.fool.com/investing/businesswire/2012/09/30/prelim...
My take is:
1) Only 14 patients were included suffering from different cancer types - this study is definitely not powered to show hard clinical outcome.
2) The 60 mg dose seems to be ideal in the Japanese study population included.
3) Tolerability looks okay although we have limited data.
But why remained only 5 out of 14 patients on study after study completion although 11 of 14 patients had decreases in tumor size compared with baseline ?
The study results are nice (be aware it was a phase 1 study), but in my opinion these results will not have any major impact on EXELs shareprice.
fool on, marsuculix
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next

Announcements

Post of the Day:
Berkshire Hathaway

Is the Market Overvalued?
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement